CYBERMED LIFE - ORGANIC  & NATURAL LIVING

Dietary Modification - Low Carbohydrate-Ketogenic

A Diet Mimicking Fasting Promotes Regeneration and Reduces Autoimmunity and Multiple Sclerosis Symptoms📎

Written by CYBERMED LIFE NEWS
Attachments:
Download this file (A Diet Mimicking Fasting Promotes Regeneration and Reduces Autoimmunity and Multiple Sclerosis Symptoms..pdf)A Diet Mimicking Fasting Promotes Regeneration and Reduces Autoimmunity and Multiple Sclerosis Symptoms..pdf[A Diet Mimicking Fasting Promotes Regeneration and Reduces Autoimmunity and Multiple Sclerosis Symptoms.]1902 kB
facebook Share on Facebook
Abstract Title:

A Diet Mimicking Fasting Promotes Regeneration and Reduces Autoimmunity and Multiple Sclerosis Symptoms.

Abstract Source:

Cell Rep. 2016 Jun 7 ;15(10):2136-46. Epub 2016 May 26. PMID: 27239035

Abstract Author(s):

In Young Choi, Laura Piccio, Patra Childress, Bryan Bollman, Arko Ghosh, Sebastian Brandhorst, Jorge Suarez, Andreas Michalsen, Anne H Cross, Todd E Morgan, Min Wei, Friedemann Paul, Markus Bock, Valter D Longo

Article Affiliation:

In Young Choi

Abstract:

Dietary interventions have not been effective in the treatment of multiple sclerosis (MS). Here, we show that periodic 3-day cycles of a fasting mimicking diet (FMD) are effective in ameliorating demyelination and symptoms in a murine experimental autoimmune encephalomyelitis (EAE) model. The FMD reduced clinical severity in all mice and completely reversed symptoms in 20% of animals. These improvements were associated with increased corticosterone levels and regulatory T (Treg) cell numbers and reduced levels of pro-inflammatory cytokines, TH1 and TH17 cells, and antigen-presenting cells (APCs). Moreover, the FMD promoted oligodendrocyte precursor cell regeneration and remyelination in axons in both EAE and cuprizone MS models, supporting its effects on both suppression of autoimmunity and remyelination. We also report preliminary data suggesting that an FMD or a chronic ketogenic diet are safe, feasible, and potentially effective in the treatment of relapsing-remitting multiple sclerosis (RRMS) patients (NCT01538355).


We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.